For research use only. Not for therapeutic Use.
Dichlorphenamide (CAT: I000784) is a medication classified as a carbonic anhydrase inhibitor. It is primarily used for the treatment of certain types of glaucoma, a condition characterized by increased intraocular pressure. By inhibiting the activity of carbonic anhydrase, an enzyme involved in the production of aqueous humor, dichlorphenamide reduces intraocular pressure and helps alleviate symptoms associated with glaucoma. Additionally, dichlorphenamide has been used off-label in the management of certain types of epilepsy and periodic paralysis, conditions in which carbonic anhydrase inhibitors can have an effect on ion transport and neuronal excitability.
| Catalog Number | I000784 |
| CAS Number | 120-97-8 |
| Molecular Formula | C6H6Cl2N2O4S2 |
| Purity | ≥95% |
| Target | Carbonic Anhydrase |
| Solubility | DMSO: ≥ 28 mg/mL |
| Storage | 3 years -20C powder |
| Reference | </br>1:Dichlorphenamide (Keveyis) for periodic paralysis. [No authors listed]Med Lett Drugs Ther. 2016 Apr 11;58(1492):50. No abstract available. PMID: 27049510 </br>2:Dichlorphenamide: A Review in Primary Periodic Paralyses. Greig SL.Drugs. 2016 Mar;76(4):501-7. doi: 10.1007/s40265-016-0559-2. Review. PMID: 26941026 </br>3:A newly approved drug for a rare group of diseases: Dichlorphenamide for periodic paralysis. Fontaine B, Phillips LH 2nd.Neurology. 2016 Apr 12;86(15):1366-7. doi: 10.1212/WNL.0000000000002430. Epub 2016 Feb 10. No abstract available. PMID: 26865522 </br>4:Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. Sansone VA, Burge J, McDermott MP, Smith PC, Herr B, Tawil R, Pandya S, Kissel J, Ciafaloni E, Shieh P, Ralph JW, Amato A, Cannon SC, Trivedi J, Barohn R, Crum B, Mitsumoto H, Pestronk A, Meola G, Conwit R, Hanna MG, Griggs RC; Muscle Study Group..Neurology. 2016 Apr 12;86(15):1408-16. doi: 10.1212/WNL.0000000000002416. Epub 2016 Feb 10. PMID: 26865514 Free PMC Article</br>5:Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Tawil R, McDermott MP, Brown R Jr, Shapiro BC, Ptacek LJ, McManis PG, Dalakas MC, Spector SA, Mendell JR, Hahn AF, Griggs RC.Ann Neurol. 2000 Jan;47(1):46-53. PMID: 10632100 </br>6:Topical ocular hypotensive activity and ocular penetration of dichlorphenamide sodium in rabbits. Lotti VJ, Schmitt CJ, Gautheron PD.Graefes Arch Clin Exp Ophthalmol. 1984;222(1):13-9. PMID: 6510719 </br>7:The role of the hydrophobicity of the substituted groups of dichlorphenamide in the development of carbonic anhydrase inhibition. Kishida K, Manabe R.Med J Osaka Univ. 1980 Mar;30(3-4):95-100. No abstract available. PMID: 7412695 </br>8:Electron-capture GLC assay of dichlorphenamide. Schmitt C, Vandenheuvel WJ, Walker RW, Plazonnet B.J Pharm Sci. 1979 Mar;68(3):381-3. PMID: 423137 </br>9:[Dichlorphenamide treatment in acute glaucoma (author/’s transl)]. Bleckmann H.Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1976 Nov 18;201(1):69-77. German. PMID: 793439 </br>10:The effect of dichlorphenamide on blood and cerebrospinal fluid acid-base state in chronic ventilatory failure. Lane DJ, Howell JB, Stretton TB.Clin Sci. 1970 Sep;39(3):391-406. No abstract available. PMID: 5459167 |
